Aptamers: from bench side research towards patented molecules with therapeutic applications
作者： Paromita Majumder , Katia N Gomes , Henning Ulrich
DOI: 10.1517/13543770903313746
关键词:
摘要: Background: RNA and DNA aptamers recognize their targets with high specificity affinity. These can be developed against almost any target protein through iterative cycles of in vitro screening a combinatorial oligonucleotide library for binding. Aptamer sequences from the final pool selection are screened pharmacological activity possible medical applications. Methods: Chemical modifications improvements identification aptamer procedures made rival antibodies diagnostic therapeutic This article reviews recent literature patents discusses properties as high-affinity binders well stability biological fluids that turns them into agents. Conclusion: The development compounds has resulted protecting use these oligonucleotides. Several paten...
fapesp.br
informahealthcare.com参考文章(92)
Benilde Cosmi, ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. Current Opinion in Molecular Therapeutics. ,vol. 11, pp. 322- 328 ,(2009)
Mats Sjöquist, Carl-Henrik Heldin, Kristofer Rubin, Arne Ostman, Tobias Sjöblom, Elisabeth Buchdunger, Kristian Pietras, Inhibition of PDGF Receptor Signaling in Tumor Stroma Enhances Antitumor Effect of Chemotherapy Cancer Research. ,vol. 62, pp. 5476- 5484 ,(2002)
Jeffrey C. Kurz, David Epstein, Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders ,(2007)
Renta Hutabarat, Robert G. Schaub, James Gilbert, vWF aptamer formulations and methods for use ,(2008)
M. Y. CHAN, C. P. RUSCONI, J. H. ALEXANDER, R. M. TONKENS, R. A. HARRINGTON, R. C. BECKER, A randomized, repeat‐dose, pharmacodynamic and safety study of an antidote‐controlled factor IXa inhibitor Journal of Thrombosis and Haemostasis. ,vol. 6, pp. 789- 796 ,(2008) , 10.1111/J.1538-7836.2008.02932.X
Jeevalatha Vivekananda, Johnathan L. Kiel, Methods and compositions for aptamers against anthrax ,(2001)
Janaína M Alves, Antonio H Martins, Arthur A Nery, Henning Ulrich, Cleber A Trujillo, Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology. Clinical Ophthalmology. ,vol. 1, pp. 393- 402 ,(2007)
Ross M. Tonkens, Christopher P. Rusconi, Administration of the reg1 anticoagulation system ,(2007)
Shawn E. Lupold, Donald S. Coffey, Yun Lin, Brian J. Hicke, Nucleic acid ligands to the prostate specific membrane antigen ,(2001)
John L. Diener, Jess Wagner-Whyte, David Fontana, Aptamers that bind thrombin with high affinity ,(2006)